Integra LifeSciences: Strong Q2 2026 Results Support Recovery Thesis (NASDAQ:IART)
· seekingalpha.com
Integra LifeSciences Holdings is a turnaround story, maintaining a BUY rating after a strong 2Q26 earnings beat and margin expansion. Click for more on IART.
I last wrote about Integra LifeSciences Holdings Corporation ( IART ) on June 22 with a BUY rating, where my thesis was that the company is a turnaround story f...